Physician profile
Scott B Snapper
NPI 1184605537
$125,936.84
in general payments reported to CMS, 2019-2025
12 companies · $2,762 in 2025
The $2,762 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $21K · 2021: $11K · 2022: $35K · 2023: $20K · 2024: $7,213 · 2025: $2,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,762 · Travel and Lodging: $1,651 · Food and Beverage: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,004.16 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,762.00 |
| Travel and Lodging | $1,651.47 |
| Food and Beverage | $157.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $52,183.02 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $22,009.12 | 2020-2023 | |
| F. Hoffmann-La Roche Ag | $20,648.81 | 2022 | |
| Amgen INC. | $10,345.74 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $7,944.45 | 2019-2022 | |
| Eli Lilly and Company | $6,831.52 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $4,759.47 | 2020 | |
| Modernatx, INC. | $1,200.00 | 2024 | |
| Abbvie INC. | $14.71 | 2019 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Snapper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.